Results 121 to 130 of about 14,279 (236)
The PROMINENT trial: swan song of the fibrates
, 2023 Post hoc analyses of previous fibrate trials have suggested that individuals with type 2 diabetes mellitus with high triglyceride levels and low HDL-cholesterol levels benefit from fibrate therapy even when the overall trial results were neutral. However
Martens, Fabrice M.A.C. +2 more
core
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism [PDF]
, 2008 Plasma lipoproteins are responsible for carrying triglycerides and cholesterol in the blood and ensuring their delivery to target organs. Regulation of lipoprotein metabolism takes place at numerous levels including via changes in gene transcription.
Kersten, A.H., Sander Kersten
core +1 more source
Acta Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
MOESM6 of Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis
, 2019 Additional file 6. Summary of findings table (fibrates compared to placebo for diabetic retinopathy)
Vânia Mozetic (7842722) +3 more
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source
Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients [PDF]
, 2019 Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis
Gomaraschi, Monica +8 more
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier +4 more
wiley +1 more source
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
, 2017 Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-
Cynthia Levy, Levy, Cynthia
core +1 more source
Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective
Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2623-2638, September 2026.ABSTRACT Primary biliary cholangitis (PBC) is an autoimmune liver disease that targets the small intrahepatic bile ducts with diagnosis based on elevated serum alkaline phosphatase (ALP) levels and the presence of anti‐mitochondrial antibodies. Untreated, it may run a progressive course to cirrhosis and hepatic decompensation, at which point liver ...
Simone I. Strasser +6 more
wiley +1 more source
Fibrates, glitazones, and peroxisome proliferator-activated receptors.
, 2010 International audienceSeveral decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 ...
Staels, Bart, Lalloyer, Fanny
core +1 more source